SR-2508

PURPOSE To report the survival results from a previous Phase I study of etanidazole (ETA) and radiotherapy in patients with… Expand

The pharmacokinetics of cyclophosphamide (CP) and several important metabolites was studied in detail in six patients receiving… Expand

Complete pharmacological data from 71 patients treated on the phase I trial of SR 2508 were analyzed to see if the dose-limiting… Expand

Sixty-five patients were entered on the long schedule of the Phase I trial of SR-2508. The planned total doses ranged from 30 to… Expand

We have investigated the effect of extreme, prolonged hypoxia on the radiosensitivity of EMT6/SF cells in vitro. As cells were… Expand

Depletion of intracellular glutathione (GSH) can enhance misonidazole (MISO) radiosensitizing efficacy both in vivo and in vitro… Expand

From March 15, through August 31, 1983, 37 patients have been entered on the RTOG Phase I trial of SR-2508. The drug was given… Expand

Abstract Using a combination of toxicological, pharmacological and radiosensitization experiments on cells in vitro and tumors in… Expand

Ten 2-nitroimidazole radiosensitizers of electron affinity equal to that of misonidazole, but differing in their octanol:water… Expand

The behavior of three 2-nitroimidazole drugs of similar electron affinity to misonidazole but with varying octanol: water… Expand